[Nonsuture small vessel replacement using microballoon catheter].

Microspheres of ovalbumin (OVA) ranging from 1 to 15 microm were prepared by emulsifying an aqueous solution of albumin in soya oil at room temperature then raising the temperature to 45 degrees C for 30 min, prior to harvesting of the microspheres. Production of OVA nanospheres with size less than 500 nm was achieved by desolvation from aqueous albumin solutions using acetone. In both cases, lactic acid was added to the starting albumin solution to stabilise the resulting particles. Utilisation of an endogenous substance avoids the use of chemical crosslinking agents such as glutaraldehyde and associated toxicological concerns. Protein coating of knitted Dacron vascular grafts was performed by impregnation of the textile structure with lactic acid-stabilised ovalbumin nanospheres thereby providing a surface potentially resistant to blood platelet adhesion but conducive to endothelialisation. Protein release testing carried out in PBS at 37 degrees C revealed that approximately 60% of the original albumin coating was retained by the Dacron graft material after 4 days and remained at this level for upto 4 weeks. Apart from the formulation of albumin microspheres for drug delivery, diagnostic applications and coating of biomedical textiles, the process of albumin stabilisation using lactic acid may be usefully applied to improve protein immobilisation on a wide range of biomaterial surfaces.

Blood Vessel Prosthesis↗

PubMed2001

Activation of circulating platelets and platelet response to activating agents in children with cyanotic congenital heart disease: their relevance to palliative systemic-pulmonary shunt.

Abnormal platelet function has been hypothesised to play a role in the haemostatic abnormalities in cyanotic congenital heart disease (CCHD) patients. Using whole blood flow cytometry we found that platelets from cyanotic patients were hyperreactive and we related such hyperreactivity directly to young age, unoperated state, high haematocrit, reduced saturation with oxygen and low platelet count. Circulating platelets from CCHD children showed significantly enhanced P-selectin expression (P<0.004) and remained more reactive to 0.2 IU/ml thrombin, 1-8 microM TRAP and 2-4 microM ADP (P<0.04), especially in younger (0-3-year-olds) patients. Such a platelet 'priming' largely concerned CCHD children who were not subjected to modified Blalock-Taussig shunts in the past (non-MBTS). Only non-MBTS cyanotic children, but not MBTS-operated patients, showed significantly higher platelet reactivity compared to controls in response to ADP or 1 microM TRAP with respect to P-selectin expression (p<0.05) and in response to all examined agonists with respect to GPIb expression (P<0.045). The enhanced P-selection expression in MBTS-operated CCHD children and reduced GPIb expression in non-MBTS patients, especially in younger patients, were positively associated with the occurrence of the polymorphic variant Pl(A2) of platelet membrane glycoprotein IIIa gene. Altered blood morphology parameters (elevated RBC, Hb, Hct and MCHC, for all P<0.0005) in CCHD children correlated with the enhanced degranulation of circulating blood platelets and their hyperreactivity in response to some agonists (P<0.05). Overall, our data encourage the reasoning that circulating platelets are remarkably hyperreactive in non-MBTS cyanotic children, which are at higher risk to often encounter platelets activation in circulation. It seems unlikely that the apparently unchanged platelet reactivity in MBTS-operated children is due to the advantageous effects of the shunt, since these patients showed neither altered haematological parameters nor improved oxygen carrying capacity. Otherwise, it may rather result from more frequent episodes of platelet degranulation and preactivation in the past, and/or post-operative enhanced platelet consumption.

Blood Vessel Prosthesis↗